What is the most recent earnings date for NVCR stock?
NOVOCURE LTD (NVCR) last reported earnings on 2/26/2026.
NASDAQ:NVCR • JE00BYSS4X48
Past quarterly earnings results for NOVOCURE LTD (NVCR), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | -0.22 | -0.42 | 47.58% | 63.93% | 174.35M | 176.82M | -1.40% | 8.11% |
| Q3 2025 | -0.33 | -0.43 | 23.15% | -17.86% | 167.204M | 162.37M | 2.98% | 7.81% |
| Q2 2025 | -0.36 | -0.39 | 8.12% | -16.13% | 158.805M | 157.29M | 0.96% | 5.62% |
| Q1 2025 | -0.31 | -0.47 | 34.54% | 13.89% | 154.994M | 149.54M | 3.65% | 11.91% |
| Q4 2024 | -0.61 | -0.35 | -73.92% | -35.56% | 161.266M | 160.97M | 0.18% | 20.54% |
| Q3 2024 | -0.28 | -0.34 | 17.78% | 39.13% | 155.095M | 146.83M | 5.63% | 21.81% |
| Q2 2024 | -0.31 | -0.42 | 26.08% | 42.59% | 150.356M | 138.54M | 8.53% | 19.28% |
| Q1 2024 | -0.36 | -0.43 | 16.51% | 28.00% | 138.503M | 134.08M | 3.30% | 13.36% |
| Q4 2023 | -0.45 | -0.53 | 15.39% | -25.00% | 133.784M | 133.81M | -0.02% | 4.19% |
| Q3 2023 | -0.46 | -0.54 | 14.10% | -84.00% | 127.321M | 131.34M | -3.06% | -2.81% |
| Q2 2023 | -0.54 | -0.51 | -5.80% | -134.78% | 126.051M | 126.74M | -0.54% | -10.54% |
| Q1 2023 | -0.50 | -0.33 | -51.47% | -1,150.00% | 122.182M | 129.82M | -5.88% | -11.14% |
| Q4 2022 | -0.36 | -0.31 | -15.72% | -44.00% | 128.4M | 130.82M | -1.85% | -3.60% |
| Q3 2022 | -0.25 | -0.27 | 6.25% | -92.31% | 131M | 132.68M | -1.27% | -1.95% |
| Q2 2022 | -0.23 | -0.15 | -55.51% | -64.29% | 140.9M | 137.69M | 2.33% | 5.54% |
| Q1 2022 | -0.04 | -0.18 | 78.21% | - | 137.5M | 136.76M | 0.54% | 2.08% |
| Q4 2021 | -0.25 | -0.10 | -141.64% | -725.00% | 133.2M | 139.81M | -4.73% | -7.50% |
| Q3 2021 | -0.13 | -0.08 | -72.81% | -244.44% | 133.6M | 144.05M | -7.25% | 0.68% |
| Q2 2021 | -0.14 | 0.01 | -1,643.92% | -800.00% | 133.5M | 144.73M | -7.76% | 15.19% |
| Q1 2021 | -0.04 | 0.02 | -296.08% | -200.00% | 134.7M | 142.15M | -5.24% | 32.32% |
| Q4 2020 | 0.04 | 0.13 | -68.49% | - | 144M | 144.12M | -0.08% | - |
| Q3 2020 | 0.09 | 0.03 | 164.73% | - | 132.7M | 122.42M | 8.40% | - |
| Q2 2020 | 0.02 | 0.00 | 622.88% | - | 115.9M | 108.15M | 7.17% | - |
| Q1 2020 | 0.04 | 0.02 | 82.99% | - | 101.8M | 104.19M | -2.29% | - |
Notes
NOVOCURE LTD (NVCR) last reported earnings on 2/26/2026.
NOVOCURE LTD (NVCR) beat EPS estimates and missed revenue estimates in the most recent quarter.
In the last 4 quarters, NOVOCURE LTD (NVCR) has beaten EPS estimates in 4 out of 4 releases.